Antares Pharma, Inc.
http://www.antarespharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Antares Pharma, Inc.
China HPV Demand Shaping Merck But Competitors Catching Up
Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.
VBP Pains Swell Prompting New China Strategy, Local Innovation Focus
As the rollout of volume-based procurement to more products brings more pain, drug makers are exploring different China strategies. One indicator, though, is clear - local innovation and distribution can’t be ignored anymore.
Deal Watch: Ikena Cuts Staff After BMS Exits IO Partnership
Plus deals involving Lipocine/Verity, Vivtex/AI Proteins, Windtree/Lee’s Pharmaceutical, Biogen/Ji Xing, Sermonix/Henlius and news from the world of technology transfer.
Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar
Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
- Transdermal
- Other Names / Subsidiaries
-
- Halozyme Therapeutics, Inc.
- Medi-Ject Corporation
- Permatec
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice